@pfeifer1982
Thanks for the input, especially for the numbers, I should have looked
Yes the Expected label population is rather larger.
I've had a another read in light of the info you've provided at the price per dose I used, it's now clear that range of prices I read about from the Decision Resources Group is for the US but using the estimated lowest EU peak sales per year using a 3% royalty the numbers are still much better than I suspected, about double.
You wrote;
"There are similar indications that Cx601 may be able to address (credit to Sanders on seekingalpha.com):
That helps me see why MSB retained the trial to;
- Rectovaginal fistulas in CD,
- Enterocutaneous fistulas in CD,
- Complex anal fistulas in non-CD,
- Intestinal ulcers in CD and
- Intestinal ulcers in Ulcerative Colitis."
"Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease"
Prochymal could address a much larger group of people.
- Forums
- ASX - By Stock
- MSB
- Licensees and MSCs
Licensees and MSCs, page-3
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B |
Open | High | Low | Value | Volume |
$1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 5460 | $1.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.26 | 978 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 5460 | 1.250 |
3 | 38390 | 1.245 |
4 | 165443 | 1.240 |
3 | 125898 | 1.235 |
6 | 135812 | 1.230 |
Price($) | Vol. | No. |
---|---|---|
1.255 | 978 | 1 |
1.260 | 191681 | 5 |
1.265 | 127480 | 6 |
1.270 | 136662 | 4 |
1.275 | 146158 | 3 |
Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online